Show simple item record

dc.contributor.authorGarcia-Lunar, Ines 
dc.contributor.authorvan der Ploeg, Hidde P
dc.contributor.authorFernández Alvira, Juan Miguel
dc.contributor.authorvan Nassau, Femke
dc.contributor.authorCastellano Vázquez, Jose Maria
dc.contributor.authorvan der Beek, Allard J
dc.contributor.authorRossello, Xavier 
dc.contributor.authorFernández-Ortiz, Antonio
dc.contributor.authorCoffeng, Jennifer
dc.contributor.authorvan Dongen, Johanna M
dc.contributor.authorMendiguren, Jose Maria
dc.contributor.authorIbáñez, Borja 
dc.contributor.authorvan Mechelen, Willem
dc.contributor.authorFuster, Valentin 
dc.date.accessioned2023-03-16T13:08:19Z
dc.date.available2023-03-16T13:08:19Z
dc.date.issued2022-10-11
dc.identifier.citationEur Heart J. 2022 Oct 11;43(38):3732-3745es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15651
dc.description.abstractTo investigate the effectiveness of a 3-year worksite lifestyle intervention on cardiovascular metrics and to study whether outcomes are influenced by baseline subclinical atherosclerosis (SA) by non-invasive imaging. A randomized controlled trial was performed to compare a lifestyle intervention with standard of care in asymptomatic middle-aged subjects, stratified by SA. The intervention consisted of nine motivational interviews during the first year, followed by three further sessions between Years 1 and 3. The primary outcome was the change in a pre-specified adaptation of the Fuster-BEWAT score (Blood pressure, Exercise, Weight, Alimentation, and Tobacco) between baseline and follow-up Years 1-3. A total of 1020 participants (mean age 50 ± 4 years) were enrolled, of whom 510 were randomly assigned to the intervention and 510 to the control group. The baseline adapted Fuster-BEWAT score was 16.2 ± 3.7 points in the intervention group and 16.5 ± 3.5 points in the control group. At Year 1, the score improved significantly in intervention participants compared with controls [estimate 0.83 (95% CI 0.52-1.15) points]. However, intervention effectiveness decreased to non-significant levels at Year 3 [0.24 (95% CI -0.10 to 0.59) points]. Over the 3-year period, the intervention was effective in participants having low baseline SA [0.61 (95% CI 0.30-0.93) points] but not in those with high baseline SA [0.19 (95% CI -0.26 to 0.64) points]. In middle-aged asymptomatic adults, a lifestyle intervention was associated with a significant improvement in cardiovascular health and behavioural metrics. The effect attenuated after 1 year as the intensity of the intervention was reduced. ClinicalTrials.gov (NCT02561065).es_ES
dc.description.sponsorshipTANSNIP-PESA is funded by Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III through an Investigator-initiated Study grant to Icahn School of Medicine from AstraZeneca. The PESA study is cofunded by the CNIC and Banco Santander. The study also received funding from the Instituto de Salud Carlos III (PI15/02019) and the European Regional Development Fund (ERDF) ‘A way to make Europe’. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033. The study funders were not involved in the study design; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the paper for publication.es_ES
dc.language.isoenges_ES
dc.publisherSaunderses_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAtherosclerosis es_ES
dc.subject.meshLife Style es_ES
dc.subject.meshAdult es_ES
dc.subject.meshBlood Pressure es_ES
dc.subject.meshExercise es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshWorkplace es_ES
dc.titleEffects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID35869885es_ES
dc.format.volume43es_ES
dc.format.number38es_ES
dc.format.page3732es_ES
dc.identifier.doi10.1093/eurheartj/ehac378es_ES
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares Carlos III (España) es_ES
dc.contributor.funderAstraZeneca es_ES
dc.contributor.funderBanco Santander es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1522-9645es_ES
dc.relation.publisherversion10.1093/eurheartj/ehac378es_ES
dc.identifier.journalEuropean heart journales_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Prevención cardiovascular a través de imagen no invasivaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI15/02019es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MICIN/AEI/10.13039/501100011033es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional